OnabotulinumtoxinA (ONA) — Competitive Intelligence Brief

OnabotulinumtoxinA (ONA) (OnabotulinumtoxinA (ONA)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin. Area: Dermatology, Neurology.

marketed Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa) Dermatology, Neurology Small molecule

Target snapshot

OnabotulinumtoxinA (ONA) (OnabotulinumtoxinA (ONA)) — Hexsel Dermatology Clinic. OnabotulinumtoxinA blocks acetylcholine release at the neuromuscular junction, paralyzing muscles and reducing dynamic wrinkles and muscle contractions.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
OnabotulinumtoxinA (ONA) TARGET	OnabotulinumtoxinA (ONA)	Hexsel Dermatology Clinic	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
Onabotulinum Toxin A	Onabotulinum Toxin A	Walter Reed National Military Medical Center	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
Abobotulinum toxin A	Abobotulinum toxin A	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
OnabotulinumtoxinA 145 UNT [Botox]	OnabotulinumtoxinA 145 UNT [Botox]	Beth Israel Deaconess Medical Center	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
Dysport® (abobotulinumtoxinA)	Dysport® (abobotulinumtoxinA)	Seoul National University Hospital	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
Onabotulinumtoxina for Injection	Onabotulinumtoxina for Injection	University of Pennsylvania	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
incabotulinumtoxinA	incabotulinumtoxinA	Multiple Sclerosis Center of Northeastern New York	marketed	Botulinum toxin type A	SNARE complex (synaptobrevin/VAMP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin class)

1. Galderma R&D · 2 drugs in this class
2. Hexsel Dermatology Clinic · 2 drugs in this class
3. Seoul National University Hospital · 2 drugs in this class
4. University of Utah · 2 drugs in this class
5. Daewoong Pharmaceutical Co. LTD. · 2 drugs in this class
6. EuBiologics Co.,Ltd · 1 drug in this class
7. Allergan · 1 drug in this class
8. GlaxoSmithKline · 1 drug in this class
9. Beth Israel Deaconess Medical Center · 1 drug in this class
10. Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 drug in this class